Cardio Vascular Medical Device Corp., an Israeli based developer of advanced cardiovascular surgery technologies, has announced that it will apply for additional patents for its proprietary steerable guidewire product for use in angioplasty procedures. The company already holds a U.S. patent for its innovative guidewire, but wants to obtain patents in Europe, Canada, and the Far East in order to penetrate a worldwide commercial marketplace for the life-saving angioplasty procedure. The steerable guidewire is applicable for all angioplasty procedures, and the potential market for related equipment exceeds $500 million.

Angioplasty is now a common procedure, performed to widen narrowed or obstructed blood vessels. It is often performed in place of, or before, more invasive and potentially life-threatening bypass surgery. Heart disease kills over 7 million people worldwide each year and is the leading cause of death for both men and women in the U.S. Angioplasty performed prior to an artery

Energy XXI (Bermuda) Limited (EXXI) Gulf Coast, Inc. (the “Company”) today September 4, 2009 announced it has commenced an exchange offer and consent solicitation in respect of its 10% Senior Notes due 2013 (the “Senior Notes”).

The Company has commenced an offer to exchange up to $360 million principal amount outstanding Senior Notes properly tendered (and not validly withdrawn) and accepted by the Company for its newly issued 16% Second Lien Junior Secured Notes due 2014 (the “Second Lien Notes”), subject to proration and reduction to $311 million principal amount of Senior Notes, depending on the aggregate principal amount of Second Lien Notes sold in a concurrent private placement.

About Energy XXI

Energy XXI is a Houston-based independent energy company engaged in the acquisition, development, exploration and production of oil and natural gas reserves in the U.S. Gulf Coast and the Gulf of Mexico. The Company an indirect wholly owned subsidiary of the

Effient (prasugrel), an anti-clotting drug developed by Eli Lilly (LLY) and Daiichi Sankyo finally received U.S. FDA approval on July 10, 2009. The drug is approved for the reduction of the risk of blood clot formation in patients undergoing angioplasty, a common procedure to unblock a clogged coronary artery.

Effient's approval has been long-awaited and is a major win for Eli Lilly. The company had filed the NDA for the product in December 2007.  The final decision took a long time coming with the FDA pushing back the approval date twice during the 18-month review period.

The approval is based on data from a pivotal phase III study (TRITON), which showed Effient to be statistically superior to Sanofi’s (SNY)/Bristol-Myers’ (BMY) Plavix in reducing the occurrence of heart attack, stroke or cardiovascular death.

However, the Effient label comes with a black box warning, which is the FDA’s strongest safety label. This includes a